You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海普瑞(09989.HK)旗下依諾肝素鈉注射液取得加拿大衞生部批准
格隆匯 12-09 18:10

格隆匯 12 月 9日丨海普瑞(09989.HK)宣佈,旗下全資附屬公司深圳市天道醫藥有限公司已就Redesca及Redesca HP(集團依諾肝素鈉注射液藥物品牌)從加拿大衞生部取得上市許可。

公告稱,集團的依諾肝素鈉注射液產品已合共在37個國家(包括加拿大)獲批並於21個國家實現銷售,同時亦可向其他15個國家的客户供應依諾肝素鈉注射液。董事會認為2020年集團的依諾肝素鈉注射液產品先後得到美國、沙特阿拉伯、中國的批准,是次加拿大的批准進一步完善了集團北美的市場佈局,將進一步加快落實集團的全球化的戰略拓展,向着成為全球領先的製藥企業不斷邁進。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account